Fig. 1.

SF1126 inhibits proliferation of parental and trastuzumab-resistant HER2-over-expressing breast cancer cells. a Parental SKBR3 HER2-overexpressing breast cancer cells (SK-parental), SKBR3-derived trastuzumab-resistant pool 2 (SK-HRp2) and clone 3 (SK-HRc3), and b parental BT474 HER2-overexpressing breast cancer cells (BT-parental), BT474-derived trastuzumab-resistant pool 2 (BT-HRp2) and pool 3 (BT-HRp3) were treated with twofold serial dilutions of SF1126 ranging from 7.5 to 120 μM for 6 days. Cell proliferation was measured using the MTS colorimetric assay, and is expressed as a percentage of untreated cells per line. Error bars represent standard deviation between six replicates. SF1126 inhibited the proliferation of parental and trastuzumab-resistant SKBR3 and BT474 HER2-overexpressing breast cancer cells